Authors' Reply to Garattini and Freemantle: "Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition"
Authors' Reply to Garattini and Freemantle: "Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition"
(2020)
Authors' Reply to Garattini and Freemantle: "Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition"
Anno:
2020
Tipologia prodotto:
Articolo in Rivista
Tipologia ANVUR:
Articolo su rivista
Lingua:
Inglese
Referee:
No
Nome rivista:
APPLIED HEALTH ECONOMICS AND HEALTH POLICY
ISSN Rivista:
1175-5652
N° Volume:
18
Numero o Fascicolo:
3
Intervallo pagine:
455-456-456
Parole chiave:
value based prices; pharmaceutical regulation
Breve descrizione dei contenuti:
Personalised drugs will increase the heterogeneity in patients’ responses to treatment; this opens new scenarios with regard to the relationship between price regulation and listing strategies by the industry. In a static framework, if the effectiveness differential across patients can be observed only by the manufacturer, the main definitions currently proposed for value-based prices lead to the same listing strategy. This is no longer true in a dynamic setting where competition by a new entrant is possible. To predict accurately the implications of alternative pricing policies, it is essential for decision makers to adopt a dynamic perspective that takes the role of competition into account.
Id prodotto:
115040
Handle IRIS:
11562/1020030
ultima modifica:
15 novembre 2022
Citazione bibliografica:
Levaggi, Rosella; Pertile, Paolo,
Authors' Reply to Garattini and Freemantle: "Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition"«APPLIED HEALTH ECONOMICS AND HEALTH POLICY»
, vol. 18
, n. 3
, 2020
, pp. 455-456-456